Anti-Lead [Clone Pb1] (60001-0.5mL)

Exposure to potentially neurotoxic levels of lead occurs in approximately 9% of American children under 6 years of age, and many urban dwellings still contain dangerous levels of lead paint. Diagnosis and treatment of chronic lead exposure has been hampered by the lack of a clear understanding of the specific mechanism of action of this toxic metal. QED Bioscience’s monoclonal antibody to lead is the first of its kind to be offered to the healthcare and research communities for development of improved diagnostic assays of lead toxicity and for investigations into the underlying mechanism of lead toxicity.